The Rhythm | Issue 17
Issue 17 | Week of 27 July 2026
No major cardiology congress fell this week. The most consequential evidence arrived through journal publication, and the five papers split cleanly into three states: established treatment hierarchies being reconsidered, proven interventions that still are not reaching enough patients, and one promising tool not yet ready for use.
Cardiology Intelligence Briefing: recalibration, not revolution
This week challenged assumptions that had begun to feel more settled than the evidence justified.
The clearest example came from stroke prevention in atrial fibrillation. Across all six available randomised trials, left atrial appendage closure reduced non-procedural bleeding but carried a higher risk of ischaemic stroke or systemic embolism than oral anticoagulation.1 This does not resolve the question for patients who genuinely cannot take anticoagulation, but it weakens the case for treating the two strategies as equivalent when anticoagulation remains viable.
An updated pathway for heart failure with preserved ejection fraction made a quieter but consequential correction.2 Finerenone now sits ahead of spironolactone as the preferred mineralocorticoid antagonist, and a new diagnostic score offers a route to initial assessment without echocardiography. None of this overturns existing care, but together it redraws the hierarchy.
Elsewhere, the problem was not deciding what should be done, but ensuring it happened. Digital prompts and decision support modestly reduced cholesterol, yet most patients with atherosclerotic disease remained above target after six months.3 Exercise testing uncovered a guideline-supported indication for valve replacement in roughly one in six patients thought to be asymptomatic with severe aortic stenosis, but around one in five with a positive test remained untreated a year later.4 The evidence identified the need for treatment more successfully than the system delivered it.
A fifth paper sat at an earlier point on that same path.5 A model built from routine clinical and exercise ECG variables appeared capable of identifying patients at very low risk of left main disease, but its performance depended heavily on an assumed disease prevalence rather than one observed in routine practice. It is a signal worth testing prospectively, not yet a basis for withholding angiography.
The lesson this week is recalibration. Some familiar strategies deserve a narrower role than they have been given, some proven interventions still fail to reach enough patients, and some promising tools remain convincing only on paper.
